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Background: Cognitive deficits have been documented in patients with bipolar disorder. Further, it has been
suggested that the degree and type of cognitive impairment differ between bipolar I and bipolar II disorder, but
data is conflicting and remains inconclusive. This study aimed to clarify the suggested differences in cognitive
impairment between patients with bipolar I and II disorder in a relatively large, clinically stable sample while
controlling for potential confounders.
Methods: 67 patients with bipolar I disorder, 43 with bipolar II disorder, and 86 randomly selected population-
based healthy controls were compared. A number of neuropsychological tests were administered, assessing verbal
and visual memory and executive functions. Patients were in a stable phase during testing.
Results: Patients with bipolar type I and type II were cognitively impaired compared to healthy controls, but there
were no statistically significant differences between the two subtypes. The strongest predictor of cognitive
impairment within the patient group was current antipsychotic treatment.
Conclusions: The present study suggests that the type and degree of cognitive dysfunction is similar in bipolar I
and II patients. Notably, treatment with antipsychotics - but not a history of psychosis - was associated with more
severe cognitive impairment. Given that patients with bipolar I disorder are more likely to be on antipsychotic
drugs, this might explain why some previous studies have found that patients with type I bipolar disorder are more
cognitively impaired than those with type II.Background
Decreased concentration and attention are common
complaints among bipolar patients. Such cognitive im-
pairment can be objectively measured with neuropsy-
chological tests [1]. Growing evidence from the last two
decades has shown that not only is cognitive dysfunction
evident during depressive or manic episodes, but the im-
pairment also persists during the euthymic phases of the
illness [2-4]. The cognitive domains most consistently
found to be impaired are executive functioning, atten-
tion, and verbal memory [5-7].
Although neurocognitive deficits have accordingly been
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reproduction in any medium, provided the orsystematic review [8] concluded that studies of patients
with bipolar disorder type II are inconsistent. Elucidating
whether cognitive dysfunction is a general trait across bi-
polar subtypes or differs between type I and II not only
has implications for rehabilitation programs, but would
also shed light on the validity of classifying bipolar sub-
types and hence pathophysiological research. It has for
example been suggested that the bipolar subtypes I and II
are qualitatively different entities with different underlying
pathophysiology [9]. If this is true, then differing patho-
physiology might be mirrored by different patterns of cog-
nitive impairment, which might serve as a more reliable
phenotype than categorical diagnoses [10]. In support of
this notion, one study found that cognitive dysfunction in
bipolar I patients differed not only in magnitude, but also
in pattern compared with bipolar II patients [11]. Whereas
both subtypes showed deficits in working memory, verbalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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controls, bipolar I patients were more severely impaired
overall and showed deficits in verbal learning and verbal
memory that were not seen in bipolar II patients. At odds
with this notion, however, a second study found quantita-
tive, but no qualitative neurocognitive differences between
the bipolar subtypes [12]. In the latter study, bipolar II
patients showed an intermediate level of performance in
verbal memory and executive functions between bipolar
I patients and healthy controls, agreeing with a view
where bipolar type I and II represent varying degrees of
disease severity on a continuum. Finally, a third study
found no differences in neurocognitive function between
bipolar type I and type II patients [13]. Here, both bi-
polar patients type I and type II performed worse than
healthy controls in most cognitive domains with the lar-
gest effect size in psychomotor speed, working memory,
verbal learning, and executive functions. Hence, this last
study suggests that cognitive function cannot be used to
discriminate between bipolar disorder type I and type II.
Apart from these relatively large studies, several smaller
studies show worse cognitive performance in bipolar type
I compared to bipolar type II patients [14,15]. However, a
recent meta-study also concluded that, with the exception
of semantic fluency and visual memory, the cognitive de-
ficits in bipolar II patients are as severe as in bipolar I
patients [16].
Given the inconsistency of available data regarding
potential cognitive differences between the two bipolar
subtypes I and II, the aim of the present study was to
compare the cognitive performance between bipolar dis-
order type I and bipolar disorder type II patients in a
relatively large and clinically stable study sample. An ex-
tensive cognitive test battery was used and all patients
had a validated diagnosis of bipolar disorder. Confoun-
ders, such as ongoing medication, residual mood symp-
toms or a history of psychosis, were controlled for. For
reference, randomly selected population-based age and
sex matched healthy controls were recruited. The use
of population-based controls is important since con-
trol groups recruited among hospital staff, students,
or through advertisements confers substantial risk for
sample bias.
Methods
The present study is part of the St. Göran bipolar pro-
ject, which provides assessment, treatment, and follow-
up of patients with bipolar disorder within the Northern
Stockholm Mental Health Service and also serves as a
basis for research into bipolar disorder. The metho-
dology has previously been outlined in detail [17-19]. A
total of 67 patients with bipolar disorder type I, 43 pa-
tients with bipolar disorder type II and 86 controls were
included in this study.Clinical assessments
Patients were assessed by a psychiatrist or resident
in psychiatry using the Affective Disorders Evaluation
(ADE), which is a standardized protocol adapted from
the Systematic Treatment Enhancement Program of
Bipolar Disorder (STEP-BD) [20]. The ADE guides the
interviewer through a systematic assessment of the pa-
tient's current and past mental state, and provides a
diagnosis according to DSM-IV criteria. The number of
lifetime affective episodes and their characteristics are
documented. Other modules assess alcohol and drug
misuse, violent behavior, childhood history, family histo-
ry, treatment history, reproductive history, and somatic
illnesses. Interpersonal violence is defined as a violent
act or serious physical threat to another person. Suicide
attempt is defined as a deliberate and serious self- injury,
including intoxication with medication.
The final diagnosis was established using LEAD
(Longitudinal observation by Experts using All Data)
[21] and confirmed by a consensus panel of two to four
experienced clinicians. Inclusion criteria for this sub-
study were bipolar I or II diagnosis. Disease severity was
assessed using the clinician rated Global Assessment of
Function (GAF) and Clinical Global Impression (CGI)
scales [22,23]. Mood stability was determined by the
treating physician's overall diagnostic judgment. The
Montgomery-Åsberg depression rating scale (MADRS)
and Young Mania rating scale (YMRS) were adminis-
tered by the neuropsychologist at the first cognitive tes-
ting session to assess residual mood symptoms. Patients
with MADRS > 14 or YMRS > 14 were not included in
this study.
Control group
Age- and sex-matched persons for each enrolled patient
were selected randomly from the national population
register by Statistics Sweden (www.scb.se) and contacted
by letter. Persons who were interested in participating in
the study contacted the study team that conducted a
preliminary telephone screening to exclude severe men-
tal health and neurological issues as well as substance
abuse. Eligible individuals were scheduled for a one-day
comprehensive assessment. Exclusion criteria for con-
trols were: 1) any on-going psychiatric or neurological
disorder; 2) current treatment with any psychotropic
drugs; 3) past history of bipolar disorder, schizophrenia,
recurrent depression or other psychiatric disorder lea-
ding to extended sick leave; 4) a first-degree relative with
schizophrenia or bipolar disorder; 5) subjects presenting
conditions that precluded magnetic resonance imaging
of the brain (e.g., metal implants, shrapnel, and certain
heart operations). The latter exclusion criterion was due
to a planned brain MRI scan for another part of the St.
Göran bipolar project. Two of the recruited controls
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and one case of alcohol addiction that was revealed at
the examination.
During the one-day assessment, a psychiatrist in-
terviewed eligible control subjects in a semi-structured
manner utilizing relevant sections of the ADE and the
Mini International Neuropsychiatric Interview (MINI)
[24] as a screen for past and present psychiatric disor-
ders. This included a screen for bipolar illness as well as
questions about socio-economic status, use of alcohol
and psychoactive substances, history of violent, criminal
or suicidal behavior (defined as deliberate and serious
self-injury including intoxication with medication). Fur-
thermore, childhood history, family history of psychiatric
disorders in first and second-degree relatives, treatment
history, reproductive history and somatic illnesses were
reviewed. The Mini International Neuropsychiatric In-
terview (MINI) [24] was used to screen for other psy-
chiatric disorders than bipolar illness. The GAF was
used to assess axis V. Included subjects also completed
three self-report questionnaires amongst which were: the
Alcohol Use Disorders Identification Test (AUDIT) [25]
and the Drug Use Disorders Identification Test (DUDIT)
[26]. Finally, all subjects underwent neuropsychological
testing by senior clinical psychology students under
supervision of the same experienced clinical psychologist
that supervised and conducted testing in the patient
group.
Neuropsychological measures
Study participants were tested using a number of
neuropsychological tests. All tests were administered
according to standard instructions. Patients were tes-
ted during a stable phase of the disorder. Administe-
ring all tests usually required two sessions with patients,
whereas all controls were tested during one single
session.
The instruments included:
a) Five tests from the Delis-Kaplan Executive
function system D-KEFS [27]. The D-KEFS is a
standardized set of tests designed to assess
executive functions including flexibility of thinking,
inhibition, problem solving, planning, impulse
control, concept formation, abstract thinking, and
creativity. It consists of nine game-like tests that
can be administrated as a complete battery or as
individual subtests. Here, we chose five out of nine
tests: Trail making test, Design fluency test, Verbal
fluency test, Color-word interference test, and
Tower test. The D-KEFS Trail making test consists
of a visual cancellation task and a series of
connect-the-circle tasks. The primary executive-
function task is condition 4 (number-letterswitching), which assesses flexibility of thinking on
a visual-motor sequencing task. The other four
conditions of this test allow the examiner to
evaluate other processes necessary for performing
the task, including visual scanning, number
sequencing, letter sequencing, and motor speed.
The D-KEFS Verbal fluency test measures the
ability to generate words fluently in a difficult
phonemic format (letter fluency), from overlearned
concepts (category fluency), and simultaneously
shifting between overlearned concepts (category
switching). The test gives information about
language skills and verbal processing ability, as well
as problem solving. The D-KEFS Design fluency
test measures the ability to draw as many different
designs as possible in 60 seconds. It comprises 3
conditions. Condition 1 provides a basic test of
design fluency, condition 2 measures both design
fluency and response inhibition, and condition 3
measures design fluency and cognitive flexibility.
Basic skills involved in this test are visual
attention, motor speed, visual-perceptual skills, and
constructional skills. The executive functions
required include visual/ spatial initiation of
problem-solving behavior, fluency, creativity,
simultaneous processing and inhibiting capacity.
D-KEFS Color-word interference test corresponds
to the Stroop color word test and primarily
measures the ability to inhibit an overlearned
verbal response, in this case reading the printed
words, and to generate the conflicting response of
naming the dissonant ink colors in which the
words are printed. This is also a test of cognitive
flexibility. The D-KEFS Tower test assesses
planning and spatial problem solving abilities such
as the ability to inhibit perseverative and impulsive
responses. Visual attention and visual-spatial ability
are fundamental skills for this task.
b) Claeson-Dahl learning and memory test was
designed to evaluate episodic memory. The test
has three dimensions. Initially the subject is asked
to learn through hearing a list of ten words. The
retention dimension involves remembering as
many words as possible from the original list and
to remember what order the words was originally
read in. Finally, in the recognition dimension, the
test person is asked to recognize the words from
the list among similar distractors.
c) In the Rey complex figure test, the test person is
asked to reproduce a complicated drawing, initially
by copying and by recall. The test draws on
cognitive domains such as memory, visuospatial
ability, attention processes, planning ability, and
incidental learning.
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Group-wise comparisons were done using ANOVA for
continuous variables and chi-square tests for dichotom-
ous variables. Bonferroni post hoc tests were used where
relevant. Associations between cognitive performance
and other variables were tested using Pearson correla-
tion or forward selection stepwise linear regression mo-
delling. Two-tailed levels of significance were used and
p < 0.05 was considered statistically significant.
Ethics
All participating patients and control subjects consented
orally and in writing to participate in the study. The pro-
ject was approved by the Stockholm Regional Ethical
Review Board and conducted in accordance with the la-
test version of the Helsinki Protocol. The healthy sub-




The most frequent pharmacological treatments and other
characteristics of the three groups are shown in Table 1.Table 1 Demographic and clinical characteristics of the study
Control (N = 86)
Age, years: mean (SD) 38.1 (14.5)
Gender (male / female) 39 / 47
Educational level,1-5: mean (SD)a 4.1
WAISinformation subtest 13,3 (2,3)
Age of onset: mean (SD)
Prior psychotic symptoms: N (%)
Suicide attempt: N (%)





Lifetime number of manic episodes: mean (SD)
Lifetime number of depressive episodes: mean (SD)
CGI: mean (SD)






a1 = less than 9 years, 2 = 9 years, 3 =12 years, 4 = 13–15 years and 5 =more than 1
bCombination of 2 or more psychotropic medications.
cMissing data for 2 patients.The three groups (bipolar I, bipolar II, and healthy con-
trols) did not differ with respect to gender, age, or edu-
cational level (Table 1). The two patient groups did not
differ in age at onset. Patients with bipolar disorder type I
showed a significantly higher occurrence of psychotic
symptoms, and were more often treated with lithium and
antipsychotics than type II. The fact that some bipolar II
patients had a history of psychotic features is explained by
psychotic symptoms during depressive episodes. Type II
patients had more depressive episodes.
All bipolar patients versus controls
The results of the neuropsychological test scores are
shown in Table 2. Overall, patients performed signi-
ficantly worse than controls on all trials in the Verbal
fluency task, aspects of the Design fluency, Tower, Rey
complex figure and Trail making tests, but not on the
Claeson-Dahl memory task. The largest effect sizes were
observed for the number sequencing and number-letter
switching conditions of the Trail making test, time first
move and time per move in the Tower test, semantic
and set-shifting trials of the Verbal fluency test and set-
shifting trial of the Design fluency test.sample
Bipolar I (N = 67) Bipolar II (N = 43) ANOVA P
F χ2
38.3 (13.5) 35.7 (12.0) 0.562 0.57
32 / 35 16 / 27 1.24 0.54
3.8 3.8 1.08 0.34
13,2 (2,3) 13,6 (2,2) 0,38 0,69
20.6 (8.4) 19.1 (8.5) 0.88 0.35
52 (78) 7 (17) 39.6 < 0.001
26 (39) 16 (38) 0.06 0.94
20 (30) 10 (23) 0.57 0.45
19 (28) 24 (56) 7.96 0.005
7 (11)c 10 (23) 3.04 0.081
3.9 (3.5) 3.6 (3.6) 0.17 0.68
1.6 (2.7) 2.2 (2.2) 1.2 0.28
3 (2.9) -
13.3 (13.2) 28.5 (31.0) 12.4 0.001
4.9 (0.9) 4.1 (0.7) 23.2 < 0.001
49 (73) 21 (49) 6.7 0.01
15 (22) 8 (19) 0.22 0.63
18 (27) 19 (44) 3.5 0.061
22 (33) 6 (14) 4.9 0.027
34 (51) 17 (40) 1.32 0.25
5 years of education.
Table 2 Performance on neuropsychological tests for patients with bipolar disorder type I, type II and healthy controls
with data presented as mean (SD) scores
Bipolar I (BPI) Bipolar II (BPII) Control (C) ANOVA P Bonferroni
post hoc test
Cohen’s D
Mean (SD) Mean (SD) Mean (SD) BPI vs C BPII vs C BPI vs BPII
Claeson-Dahl1 N = 57 N = 42 N = 84
Learning 46.9 (11.0) 47.2 (12.1) 49.3 (10.3) 1.04 0.35
Retention 48.0(12.8) 44.0 (12.5) 48.0 (10.4) 1.97 0.14
Recognition 9.6 (0.8) 9.7 (0.7) 9.8 (0.6) 1.19 0.31
Colour-Word2 N = 60 N = 40 N = 82
Colours 8.7 (3.5) 9.1 (2.2) 9.8 (2.3) 2.66 0.072
Colour names 9.7 (2.8) 10.5 (1.9) 10.1 (2.5) 1.28 0.28
Inhibition 9.6 (3.7) 9.9 (2.6) 11.7 (2.5) 9.70 <0.001 BPI, BPII < C 0.54 0.55 0.09
Inhibition and set-shifting 9.6 (3.4) 10.1 (2.7) 11.3 (2.6) 6.73 0.002 BPI < C 0.56 0.45 0.16
Design Fluency2 N = 65 N = 40 N = 84
Draw designs 11.1 (3.2) 11.3 (2.4) 11.7 (2.7) 0.97 0.38
Connect the dots 11.1 (3.0) 11.2 (3.0) 11.5 (2.3) 0.48 0.62
Set-shifting 10.9 (2.7) 11.5 (2.7) 13.1 (2.7) 12.87 <0.001 BPI, BPII < C 0.81 0.59 0.22
Rey Complex Figure 3 N = 60 N = 42 N = 80
Copy score 33.6 (2.7) 32.7 (3.1) 32.7 (3.1) 0.28 0.76
Time to draw figure 221.8 (140.3) 199.6 (101.3) 159.7 (71.6) 6.35 0.002 BPI > C 0.56 0.45 0.18
Immediate recall 41.8 (14.0) 44.4 (15.0) 48.4 (12.9) 4.94 0.008 BPI < C 0.49 0.29 0.18
30 minute recall 43.4 (14.8) 43.0 (14.2) 46.9 (13.2) 2.24 0.11
Recognition 43.4 (11.5) 44.5 (13.5) 50.2 (11.3) 6.84 0.001 BPI, BPII < C 0.60 0.46 0.08
Tower4 N = 58 N = 35 N = 56
Total score 10.5 (3.6) 11.1 (3.3) 11.9 (2.4) 3.22 0.043 BPI < C 0.46 0.28 0.17
Rule violations 1.3 (3.0) 1.2 (4.1) 0.3 (0.7) 2.44 0.091
Time first move 9.0 (3.5) 8.5 (2.3) 10.6 (2.8) 7.01 0.001 BPI, BPII < C 0.50 0.82 −0.17
Time per move 7.6 (3.6) 8.5 (2.7) 10.3 (2.3) 13.36 <0.001 BPI, BPII < C 0.89 0.72 0.28
Move accuracy 11.4 (3.3) 10.6 (2.6) 10.3 (2.0) 2.33 0.10
TMT2 N = 65 N = 41 N = 85
Visual Scanning 10.5 (2.9) 11.1 (1.8) 10.8 (2.3) 0.85 0.43
Number Sequencing 8.8 (3.6) 10.0 (2.8) 11.5 (2.4) 15.18 <0.001 BP, BPII < C 0.88 0.58 0.37
Letter Sequencing 9.3 (3.1) 9.8 (2.8) 11.1 (2.7) 7.72 0.001 BPI < C 0.62 0.47 0.17
Number-Letter Switching 9.1 (3.0) 9.4 (2.9) 11.6 (1.6) 22.99 <0.001 BPI, BPII < C 1.04 0.94 0.10
Motor Speed 11.4 (2.2) 11.6 (2.4) 11.8 (1.6) 0.92 0.40
Verbal Fluency2 N = 65 N = 43 N = 83
Phonetic 12.0 (4.6) 12.4 (4.0) 13.7 (3.3) 3.88 0.022 BPI < C 0.42 0.35 0.09
Semantic 12.3 (4.4) 12.4 (4.0) 16.0 (3.2) 20.72 <0.001 BPI, BPII < C 0.96 0.99 0.02
Set-shifting 10.9 (3.6) 11.5 (3.1) 13.7 (3.4) 12.98 <0.001 BPI, BPII < C 0.91 0.68 0.18
1Mean scores are t-scores for learning and retention and raw scores for recognition.
2Mean scores are demographics corrected standard scores.
3Mean scores are raw scores for copy score and time to draw figure and t-scores for recall and recognition variables.
4Mean scores are demographics corrected standard scores except rule violations, which is a raw score.
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There were no statistically significant differences bet-
ween bipolar I and bipolar II patients. Bipolar I patientsdid show an overall tendency towards more impairment
as demonstrated by the post-hoc tests and magnitude of
effect sizes.
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To reduce the number of comparisons, further analysis
was restricted to those neuropsychological test variables
where a significant difference between patients groups
and the control groups was demonstrated. Since no sig-
nificant differences were shown between patients with
type I and type II bipolar disorder, the patient samples
were pooled for the remaining analyses. Treatments with
psychotropic drugs, residual mood symptoms and a his-
tory of psychosis have all previously been shown to in-
fluence cognitive performance. Linear regression analysis
using a step-wise procedure with the most prevalent
drug classes in the patient group, history of psychotic
symptoms and MADRS and YMRS scores as indepen-
dent and neuropsychological test scores as dependent
variables were performed. Anxiety disorder or ADHD
diagnosis were also included to control for co-morbidity.
There were no significant associations between cog-






Rey complex figure Time to draw figure 1
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Forward selection step-wise linear regression analysis of the each test variable was
disorder and ADHD co-morbidity and use or non-use of each medication group as i
listed in the table. 1Variable was log-transformed prior to analysis.anticonvulsants. A single association was found between
treatment with antidepressants and the letter sequen-
cing part of the Trail making test. Conversely, treatment
with antipsychotics was associated with worse perform-
ance on the time to draw parameter of the Rey complex
figure test, number sequencing, letter sequencing and
number-letter switching conditions of the Trail making
test and all trials of the Verbal fluency test. Examining
the patient group, there were no significant associa-
tions between cognitive test performance and MADRS
score, history of psychosis or ADHD diagnosis. Anxiety
disorder diagnosis was associated with worse perfor-
mance on the phonetic part of the Verbal fluency test.
Current mania symptoms were associated with worse
performance on the time to draw parameter of the
Rey complex figure test, the inhibition trial of the
color-word test and the phonetic and semantic parts
of the Verbal fluency test. The results of this analysis
are shown in Table 3.t data
β t df p
−0.22 −2.06 1 0.042
−0.25 −2.42 1 0.017
0.29 2.92 1 0.004
0.21 2.12 1 0.037
−0.24 −2.25 1 0.027
−0.30 −2.90 1 0.005
−0.45 −4.50 1 <0.001
−0.25 −2.50 1 0.014
−0.23 −2.18 1 0.032
−0.27 −2.85 1 0.005
−0.27 −2.88 1 0.005
−0.24 −2.49 1 0.015
−0.29 −2.90 1 0.005
−0.26 −2.62 1 0.010
−0.23 −2.20 1 0.030
conducted using MADRS, YMRS, subdiagnosis, history of psychosis, anxiety
ndependent variables. Only significant predictors for each test variable are
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There are three main findings in the present study. First,
the study confirmed previous findings that clinically
stable patients with bipolar disorder showed impairment
in inhibition, in set-shifting, in verbal fluency and in vis-
ual recall compared to healthy age-matched controls. Bi-
polar patients also gave more rapid responses during the
Tower test and showed impulsivity on the Color-word
test, yet were slower in drawing the Rey figure. Second,
there were no major differences between the type I and
type II subtypes of bipolar disorder. Third, treatment
with antipsychotic drugs was associated with worse per-
formance in verbal fluency, in inhibition, in set-shifting
and a longer time to draw the Rey figure.
The patient group as a whole thus performed worse
than controls on all the included tests from the D-KEFS
battery. These tests tap different aspects of executive
function and hence confirm previously observed deficits
in several aspects of executive function including re-
sponse inhibition, attention, working memory, cognitive
flexibility, and spatial planning [3]. Further, patients per-
formed worse on both the immediate recall and recogni-
tion parts of the Rey complex figure test. This was less
apparent in the Claeson-Dahl test, which indicated re-
duced performance on visual but not verbal memory
tasks. However, this finding may be confounded by dif-
ferences in test sensitivity and the Claeson-Dahl test
may not be a demanding enough test to detect verbal
learning and memory deficits in the present patient sam-
ple. Other tests, such as the California verbal learning
task may provide more sensitive alternatives [28].
Pertaining to the putative differences between bipolar
I and II disorder, we observed no statistically significant
differences. This is in line with the study by Dittmann
et al. [13] and a recent study by Xu et al. [29], but con-
flicts the results by Torrent et al. [12] and Simonsen
et al. [11]. One possible explanation for these conflicting
findings is that the results are confounded by anti-
psychotic medication. In the present study, antipsychotic
medication was coupled to significantly lower cognitive
performance. This corroborates previous studies that
have demonstrated that antipsychotics may have adverse
effects on cognitive function in patients with bipolar
disorder [30-32]. Given that bipolar I patients are more
frequently treated with antipsychotics than bipolar II pa-
tients, this may be part of the explanation for previous
observations of greater cognitive impairment in type I as
compared to type II bipolar disorder.
A number of studies have linked psychotic features to
more chronic and severe presentations of bipolar dis-
order [33]. Since impaired neurocognitive function has
been linked to poor functional outcome, psychotic fea-
tures and cognitive dysfunction may be connected. A
recent study comparing psychotic and non-psychoticpatients with schizophrenia, schizoaffective disorder, and
bipolar disorder found that a history of psychosis was a
stronger predictor than diagnostic group of neuropsy-
chological test performance [34]. However, due to an al-
most complete overlap between history of psychosis and
treatment with antipsychotic medication in that study, it
was not possible to rule out an effect of antipsychotic
drugs in that study.
Importantly and at odds with previous findings, we did
not observe any association between previous psychotic
symptoms and cognitive performance. In the present
study, the overlap between history of psychosis and treat-
ment with antipsychotic medication was only partial and
could therefore be statistically controlled for. Indeed, our
findings suggest that current treatment with antipsychotic
medication predict neurocognitive test performance better
than history of psychotic symptoms. Of interest is also
the fact that the doses of antipsychotics in our study
were low to moderate (data not shown), making this
association all the more clinically important when de-
ciding on treatment.
Strengths and limitations
A particular strength of the present study is the
population-based control sample. Comparisons between
healthy controls and patients may be biased if the con-
trols are unrepresentative of the general population. The
use of a population-based control sample from the same
catchment area indicates that the observed differences
are unlikely to be the result of sampling bias, but reflect
actual differences in neurocognitive function between
patients and controls. Further, the meticulous diagnostic
assessment ensures that the division in bipolar I and II
disorder is as accurate as possible. However, it should be
noted that the diagnostic procedure used here as not been
analysed for reliability estimates which somewhat limits
the conclusions that can be drawn regarding diagnostic
accuracy. The sample is sufficiently large to avoid type II
errors [8]. Finally, the present study used an extensive test
battery providing a broad neurocognitive profiling.
With regards to the previous studies on cognitive
function in bipolar II disorder our patient sample had a
relatively young age of onset, 20 years versus approxi-
mately 28–30 years [11-13]. To a lesser extent this was
also true for the bipolar I group with a mean age of on-
set of 19 years versus 24–28 years in previous studies.
However, the mean age at first episode in our patient
group was comparable to previously published demo-
graphic data [35]. Earlier age of onset has been linked to
a more severe form of the disorder [36,37], although a
late onset has been linked to a more pronounced cogni-
tive deficit [38].
The cut-off for present mood symptoms used in this
study was less strict than previous studies and lingering
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mance [39]. However, the mean scores for MADRS and
YMRS were well below a more strict definition of euthy-
mia [40] and the present study failed to demonstrate
meaningful correlations between residual depressive
symptoms and cognitive function. For residual manic
symptoms, we observed a negative correlation between
performance on the Verbal fluency test and YMRS score.
Previous studies on neurocognitive function bipolar II
disorder have found small [12] or no [11,13] effects of
subsyndromal depressive and manic symptoms on cogni-
tive function.
Our findings regarding the effects of current medica-
tion may be confounded by the fact that most patients
are treated with more than one class of psychotropic
medication. However, our analysis of combination ther-
apy did not indicate any such effects. In addition, medi-
cation may obscure the influence of other factors, e.g.,
psychotic symptoms that may otherwise have been cor-
related with cognitive test scores. The fact that our study
was cross-sectional also limits the conclusions that can
be drawn regarding the relationship between cognitive
function and clinical variables or treatment. Future longi-
tudinal studies on the present patient sample may provide
valuable information on the progression and significance
of neurocognitive dysfunctions in the clinical setting.
Conclusions
In conclusion, we found similar types and degrees of
cognitive dysfunction in bipolar I and bipolar II patients
as compared to healthy controls. Overall, the magnitude
and cognitive domains affected are in agreement with
previously published work on euthymic bipolar patients.
We also found a greater degree of impairment in pa-
tients treated with antipsychotics, but no correlation
between history of psychosis and cognitive function.
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